Table 4 SNP versus treatment logistic regression
From: Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease
Treatment | IRGM | ATG16L1 | NOD2 | XBP1 | LRRK2/MUC19 | CCR6 | IL23 | STAT3 | NCF4 |
|---|---|---|---|---|---|---|---|---|---|
Requirement | |||||||||
Infliximab | ns | ns | OR 0.62, CI 0.41–0.95 | ns | ns | ns | ns | ns | ns |
Adalimumab | OR 0.57, CI 0.36–0.91 | OR 2.4, CI 1.3–4.4 | ns | ns | ns | ns | ns | ns | ns |
Side-effects | |||||||||
Infliximab | ns | ns | ns | ns | ns | ns | ns | OR 0.19, CI 0.05–0.78 | ns |
Adalimumab | ns | ns | ns | ns | ns | ns | ns | ns | ns |
Loss of response | |||||||||
Infliximab | ns | ns | ns | ns | ns | ns | ns | ns | ns |
Adalimumab | ns | ns | ns | ns | ns | ns | ns | ns | ns |
Primary non response | |||||||||
Infliximab | OR 2.8, CI 1.1–7.0 | ns | ns | OR 3.8, CI 1.2–12.0 | ns | ns | ns | ns | ns |
Adalimumab | ns | ns | ns | ns | ns | ns | ns | ns | ns |